Hjem › Follikulært lymfom › Georgia
Kliniske studier for Follikulært lymfom i Georgia
15 studier for Follikulært lymfom søker deltakere på steder i Georgia.
Byer i Georgia
Offisiell studietekst (engelsk)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Augusta University Medical Center, Augusta
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07215910Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05006716A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Emory University Hospital, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07226843A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Atlanta
- Research Site, Macon
RekruttererFase 3
Alder 18 til 130 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06549595Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Piedmont Healthcare, Atlanta
- Winship Cancer Institute, Atlanta
RekruttererFase 3
Alder 12 til 100 · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06784752Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Emory University Hospital/Winship Cancer Institute, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Emory University, Atlanta
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Augusta University Medical Center, Augusta
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05826535Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT05131022A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta
- Southeastern Regional Medical Center, Newnan
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mai 2026 · NCT06911502SynKIR-310 for Relapsed/Refractory B-NHL
- Winship Cancer Institute of Emory University, Atlanta
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 14. apr. 2026 · NCT06544265Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
- Emory University Hospital/Winship Cancer Institute, Atlanta
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. feb. 2026 · NCT04883437SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Atlanta
- Massive Bio SYNERGY-AI site, Savannah
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.